Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$6.80 USD
-0.05 (-0.73%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $5.82 -0.98 (-14.41%) 6:30 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Applied Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -119.76 | -82.51 | -105.58 | -93.96 | -45.51 |
Depreciation/Amortization & Depletion | 2.47 | 4.03 | 4.70 | 2.93 | 0.02 |
Net Change from Assets/Liabilities | -1.81 | -9.29 | -1.02 | 4.80 | 3.21 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 63.93 | 9.67 | 11.18 | 8.02 | 5.97 |
Net Cash From Operating Activities | -55.17 | -78.09 | -90.73 | -78.21 | -36.31 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 13.87 | 13.17 | 12.43 | -19.47 | -20.01 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 13.87 | 13.17 | 12.43 | -19.47 | -20.01 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 74.85 | 27.86 | 75.00 | 135.92 | 58.91 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -1.86 | -3.27 | -4.72 | -2.15 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.55 | 3.11 | 4.43 | 2.52 | -2.50 |
Net Cash from Financing Activities | 74.54 | 27.69 | 74.72 | 136.29 | 56.42 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 33.24 | -37.23 | -3.58 | 38.62 | 0.10 |
Cash at Beginning of Period | 16.66 | 53.89 | 57.47 | 18.85 | 18.75 |
Cash at End of Period | 49.90 | 16.66 | 53.89 | 57.47 | 18.85 |
Diluted Net EPS | -1.42 | -2.18 | -4.12 | -4.28 | -3.55 |
Fiscal Year End for Applied Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -119.76 | -82.08 | -39.71 | -10.14 | -82.51 |
Depreciation/Amortization & Depletion | 2.47 | 2.07 | 1.56 | 0.88 | 4.03 |
Net Change from Assets/Liabilities | -1.81 | -3.50 | -1.53 | 0.68 | -9.29 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 63.93 | 45.35 | 16.23 | 1.59 | 9.67 |
Net Cash From Operating Activities | -55.17 | -38.17 | -23.44 | -6.99 | -78.09 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 13.87 | 13.87 | 13.87 | 13.87 | 13.17 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 13.87 | 13.87 | 13.87 | 13.87 | 13.17 |
Uses of Funds
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 74.85 | 44.94 | 27.91 | 0.00 | 27.86 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -1.86 | -1.39 | -0.93 | -0.62 | -3.27 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.55 | 1.55 | 1.55 | 0.00 | 3.11 |
Net Cash from Financing Activities | 74.54 | 45.10 | 28.53 | -0.62 | 27.69 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 33.24 | 20.80 | 18.96 | 6.26 | -37.23 |
Cash at Beginning of Period | 16.66 | 16.66 | 16.66 | 16.66 | 53.89 |
Cash at End of Period | 49.90 | 37.46 | 35.62 | 22.92 | 16.66 |
Diluted Net EPS | -0.40 | -0.47 | -0.37 | -0.18 | 0.06 |